• 中文核心期刊要目总览
  • 中国科技核心期刊
  • 中国科学引文数据库(CSCD)
  • 中国科技论文与引文数据库(CSTPCD)
  • 中国学术期刊文摘数据库(CSAD)
  • 中国学术期刊(网络版)(CNKI)
  • 中文科技期刊数据库
  • 万方数据知识服务平台
  • 中国超星期刊域出版平台
  • 国家科技学术期刊开放平台
  • 荷兰文摘与引文数据库(SCOPUS)
  • 日本科学技术振兴机构数据库(JST)
高文聪, 马昕, 王鹏, 何晓妍, 郑永唐, 刘丰亮, 郑昌博. 2021: 卡托普利减轻了感染SARS-CoV-2的高血压小鼠的肺部炎症. 动物学研究, 42(5): 633-636. DOI: 10.24272/j.issn.2095-8137.2021.206
引用本文: 高文聪, 马昕, 王鹏, 何晓妍, 郑永唐, 刘丰亮, 郑昌博. 2021: 卡托普利减轻了感染SARS-CoV-2的高血压小鼠的肺部炎症. 动物学研究, 42(5): 633-636. DOI: 10.24272/j.issn.2095-8137.2021.206
Wen-Cong Gao, Xin Ma, Peng Wang, Xiao-Yan He, Yong-Tang Zheng, Feng-Liang Liu, Chang-Bo Zheng. 2021: Captopril alleviates lung inflammation in SARS-CoV-2-infected hypertensive mice. Zoological Research, 42(5): 633-636. DOI: 10.24272/j.issn.2095-8137.2021.206
Citation: Wen-Cong Gao, Xin Ma, Peng Wang, Xiao-Yan He, Yong-Tang Zheng, Feng-Liang Liu, Chang-Bo Zheng. 2021: Captopril alleviates lung inflammation in SARS-CoV-2-infected hypertensive mice. Zoological Research, 42(5): 633-636. DOI: 10.24272/j.issn.2095-8137.2021.206

卡托普利减轻了感染SARS-CoV-2的高血压小鼠的肺部炎症

Captopril alleviates lung inflammation in SARS-CoV-2-infected hypertensive mice

  • 摘要: 严重急性呼吸系统综合症冠状病毒2型 (SARS-CoV-2) 是导致全球2019冠状病毒病 (COVID-19) 大流行的病原体。大量研究表明,心血管疾病可能会影响COVID-19的进展。在该研究中,我们使用感染了 SARS-CoV-2 的高血压小鼠模型研究了高血压对病毒复制和 COVID-19 进展的影响。结果显示,在高血压小鼠的肺中SARS-CoV-2的复制延迟。相比之下,用抗高血压药物卡托普利治疗的高血压小鼠的SARS-CoV-2 复制与感染了SARS-CoV-2 的正常血压小鼠的病毒复制相似。此外,抗高血压治疗减轻了由 SARS-CoV-2 复制引起的IL-1β上调和免疫细胞浸润增加。在感染 SARS-CoV-2 的血压正常小鼠和高血压小鼠之间没有观察到肺部炎症的差异。因此,我们的研究结果初步表明,卡托普利治疗可能会缓解COVID-19的进展,但不会影响病毒复制。

     

    Abstract: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the etiologic agent responsible for the global coronavirus disease 2019 (COVID-19) pandemic. Numerous studies have demonstrated that cardiovascular disease may affect COVID-19 progression. In the present study, we investigated the effect of hypertension on viral replication and COVID-19 progression using a hypertensive mouse model infected with SARS-CoV-2. Results revealed that SARS-CoV-2 replication was delayed in hypertensive mouse lungs. In contrast, SARS-CoV-2 replication in hypertensive mice treated with the antihypertensive drug captopril demonstrated similar virus replication as SARS-CoV-2-infected normotensive mice. Furthermore, antihypertensive treatment alleviated lung inflammation induced by SARS-CoV-2 replication (interleukin (IL)-1β up-regulation and increased immune cell infiltration). No differences in lung inflammation were observed between the SARS-CoV-2-infected normotensive mice and hypertensive mice. Our findings suggest that captopril treatment may alleviate COVID-19 progression but not affect viral replication.

     

/

返回文章
返回